E. Denk’s research while affiliated with Institute of Science and Technology Austria and other places

... free intervals, poor social support which easily complicate long-term compliance. As there is good evidence for a positive effect of lithium also on the reduction of mortality ᎏ especially suicide mortality ᎏ in patients with affective disorders Ž non-adherence is obviously a relevant issue Mc-Creadie et al., 1985;Coppen et al., 1991;Muller-Oerlinghausen et al., 1992Lenz et al., 1994;Ahrens et al., 1995;Johnson and McFar-. land, 1996 . ...

Reference:

Non-adherence with long-term prophylaxis: A 6-year naturalistic follow-up study of affectively ill patients

... The ameliorating influence of CBZ on overactivity, aggression or poor impulse control may contribute to its effects on schizophreniform psychoses, especially those with aggressive outbursts (Neppe 1982; Hakola and Laulumaa 1982; Luchins 1981 Luchins , 1983a 1983b; ), overactivity (Reid et al 1981; Gardner and Cowdry 1986b) and with other affective symptoms (Takezaki and Hanaoka 1971; Placidi et al 1986). Although there are studies testing the efficacy of CBZ as a monotherapeutic agent after the withdrawal of neuroleptics (Sramek et al 1988; Carpenter et al 1991), more commonly CBZ has been added to preexisting neuroleptic therapy (Raju 1984; Tsuneizumi et al 1986; Dose et al 1987; Schulz et al 1989; Mair et al 1990; Kunovac et al 1991; Meszaros et al 1990b; 1990c) -particularly in studies dealing with chronic schizophrenics (Herrera et al 1987a; 1987b; Wetterling 1987; Meszaros et al 1991b; 1991c). In some experiments CBZ has been shown to be useful in the improvement ofschizophrenic negative symptoms especially in anhedonia or social retreatment (Hakola and Laulumaa 1982; Klein et al 1984; Ballenger and Post 1984; Herrera et al 1987a; 1987b; Sramek et al 1988; Okuma et al 1989). ...

Reference:

The use of carbamazepine in the treatment of schizophrenic and schizoaffective psychoses: A review

... The ameliorating influence of CBZ on overactivity, aggression or poor impulse control may contribute to its effects on schizophreniform psychoses, especially those with aggressive outbursts (Neppe 1982; Hakola and Laulumaa 1982; Luchins 1981 Luchins , 1983a 1983b; ), overactivity (Reid et al 1981; Gardner and Cowdry 1986b) and with other affective symptoms (Takezaki and Hanaoka 1971; Placidi et al 1986). Although there are studies testing the efficacy of CBZ as a monotherapeutic agent after the withdrawal of neuroleptics (Sramek et al 1988; Carpenter et al 1991), more commonly CBZ has been added to preexisting neuroleptic therapy (Raju 1984; Tsuneizumi et al 1986; Dose et al 1987; Schulz et al 1989; Mair et al 1990; Kunovac et al 1991; Meszaros et al 1990b; 1990c) -particularly in studies dealing with chronic schizophrenics (Herrera et al 1987a; 1987b; Wetterling 1987; Meszaros et al 1991b; 1991c). In some experiments CBZ has been shown to be useful in the improvement ofschizophrenic negative symptoms especially in anhedonia or social retreatment (Hakola and Laulumaa 1982; Klein et al 1984; Ballenger and Post 1984; Herrera et al 1987a; 1987b; Sramek et al 1988; Okuma et al 1989). ...

Reference:

The use of carbamazepine in the treatment of schizophrenic and schizoaffective psychoses: A review

... In this study, carried out jointly at the Department of Psychiatry of the University of Vienna and the Department of Psychiatry of the Freie Universitat Berlin, a cohort of patients suffering from DSM-III-R affective and schizoaffective disorders was followed up 6 years after baseline examination. In both departments there are specialized lithium-outpatient clinics with regular basic monitoring of prophylactic medication: baseline documentation includes sociodemographic Ž data, illness data and treatment data Muller-Oerlinghausen, 1977;Simhandl et al., 1989; . Berghofer et al., 1994 ; 3 monthly visits by doctors include control of lithium serum levels and qualitative evaluation of side effects; and other laboratory control subjects are stressed at least once per year. ...

Reference:

Non-adherence with long-term prophylaxis: A 6-year naturalistic follow-up study of affectively ill patients

... The review yielded 11 studies on the use of CBZ in maintenance treatment of BD, as shown in Table 3 16,[28][29][30][31][32][33][34][35][36][37] . Fifteen clinical evaluation scales were used, the most common of which were the Bech-Rafaelsen Mania Scale (BRMAS) 28,34 , Bech Rafaelsen Melancholia Scale (BRMES) 28,34 , Goal Attainment Scale (GAS) 31,32 , and CGI 29,34 . ...

Reference:

Carbamazepine in the treatment of bipolar disorder: a systematic review

... If one considers only randomized clinical trials comparing the use of antipsychotics versus antipsychotics + carbamazepine, the literature is scarce in the investigation of the effectiveness and safety of this combination in the treatment of schizophrenia. Only two studies, to our knowledge, recommend the use of carbamazepine + FGA [20,21]. However, the number of patients studied was considerably small. ...

Reference:

Factors associated with expression of extrapyramidal symptoms in users of atypical antipsychotics